The protective effect of EGb 761 in isolated ischemic/reperfused rat hearts: A link between cardiac function and nitric oxide production

E. Varga, Annamaria Bodi, P. Ferdinándy, Marie Therese Droy-Lefaix, Ingolf E. Blasig, A. Tósaki

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

This study was conducted to evaluate the effect of Ginkgo biloba extract (EGb 761) on the nitric oxide (NO) production in relation to the recovery of postischemic cardiac function in isolated working rat hearts. Rats were orally treated with various doses (25, 50, 75, and 100 mg/kg/day) of EGb 761 for 10 days. Hearts were isolated in 'working mode' and subjected to 30-min ischemia followed by 120 rain of reperfusion. EGb 761 inhibited NO production measured by electron spin-resonance spectroscopy (ESR), and improved the recovery of postischemic cardiac function (coronary flow, aortic flow, left ventricular developed pressure and its first derivative) in the ischemic/reperfused myocardium. Thus in rats treated with 25, 50, 75, and 100 mg/kg/day of EGb 761 and in hearts subjected to 30-min ischemia followed by 120 min of reperfusion, aortic flow was increased from its postischemic drag- free control value of 8.0 ± 0.4 to 8.6 ± 0.4 ml/min (NS), 17.3 ± 0.9 ml/min (p <0.05), 21.5 ± 1.1 ml/min (p <0.05), and 23.6 ± 1.2 ml/min, respectively. The same recovery in postischemic coronary flow, left ventricular developed pressure, and its first derivative also was observed. In the initial phase of reperfusion, NO production measured by ESR was reduced by 85% in the 75 mg/kg/day of EGb 761-treated group in comparison with the drug-free ischemic/reperfused hearts. Inducible NO synthase (iNOS) messenger RNA (mRNA) measured by reverse transcription-polymerase chain reaction (RT-PCR) also was reduced by 41 and 58% in the groups treated with 75 and 100 mg/kg/day of EGb 761, respectively. Our findings show that EGb 761 directly acts as an NO scavenger and concomitantly inhibits the expression of iNOS mRNA. Thus, EGb 761 may act as a potent inhibitor of NO production under the condition of ischemia/reperfusion, improving the recovery of postischemic cardiac function.

Original languageEnglish
Pages (from-to)711-717
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Volume34
Issue number5
DOIs
Publication statusPublished - Nov 1999

Fingerprint

Nitric Oxide
Reperfusion
Ischemia
Electron Spin Resonance Spectroscopy
Ventricular Pressure
Ginkgo biloba extract 761
Messenger RNA
Rain
Nitric Oxide Synthase Type II
Nitric Oxide Synthase
Reverse Transcription
Myocardium
Polymerase Chain Reaction
Pharmaceutical Preparations

Keywords

  • Cardiac function
  • iNOS mRNA
  • Ischemia
  • Nitric oxide
  • Rat heart
  • Reperfusion

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

The protective effect of EGb 761 in isolated ischemic/reperfused rat hearts : A link between cardiac function and nitric oxide production. / Varga, E.; Bodi, Annamaria; Ferdinándy, P.; Droy-Lefaix, Marie Therese; Blasig, Ingolf E.; Tósaki, A.

In: Journal of Cardiovascular Pharmacology, Vol. 34, No. 5, 11.1999, p. 711-717.

Research output: Contribution to journalArticle

@article{31d92b6fa0be46ee81e34ecbc12927fe,
title = "The protective effect of EGb 761 in isolated ischemic/reperfused rat hearts: A link between cardiac function and nitric oxide production",
abstract = "This study was conducted to evaluate the effect of Ginkgo biloba extract (EGb 761) on the nitric oxide (NO) production in relation to the recovery of postischemic cardiac function in isolated working rat hearts. Rats were orally treated with various doses (25, 50, 75, and 100 mg/kg/day) of EGb 761 for 10 days. Hearts were isolated in 'working mode' and subjected to 30-min ischemia followed by 120 rain of reperfusion. EGb 761 inhibited NO production measured by electron spin-resonance spectroscopy (ESR), and improved the recovery of postischemic cardiac function (coronary flow, aortic flow, left ventricular developed pressure and its first derivative) in the ischemic/reperfused myocardium. Thus in rats treated with 25, 50, 75, and 100 mg/kg/day of EGb 761 and in hearts subjected to 30-min ischemia followed by 120 min of reperfusion, aortic flow was increased from its postischemic drag- free control value of 8.0 ± 0.4 to 8.6 ± 0.4 ml/min (NS), 17.3 ± 0.9 ml/min (p <0.05), 21.5 ± 1.1 ml/min (p <0.05), and 23.6 ± 1.2 ml/min, respectively. The same recovery in postischemic coronary flow, left ventricular developed pressure, and its first derivative also was observed. In the initial phase of reperfusion, NO production measured by ESR was reduced by 85{\%} in the 75 mg/kg/day of EGb 761-treated group in comparison with the drug-free ischemic/reperfused hearts. Inducible NO synthase (iNOS) messenger RNA (mRNA) measured by reverse transcription-polymerase chain reaction (RT-PCR) also was reduced by 41 and 58{\%} in the groups treated with 75 and 100 mg/kg/day of EGb 761, respectively. Our findings show that EGb 761 directly acts as an NO scavenger and concomitantly inhibits the expression of iNOS mRNA. Thus, EGb 761 may act as a potent inhibitor of NO production under the condition of ischemia/reperfusion, improving the recovery of postischemic cardiac function.",
keywords = "Cardiac function, iNOS mRNA, Ischemia, Nitric oxide, Rat heart, Reperfusion",
author = "E. Varga and Annamaria Bodi and P. Ferdin{\'a}ndy and Droy-Lefaix, {Marie Therese} and Blasig, {Ingolf E.} and A. T{\'o}saki",
year = "1999",
month = "11",
doi = "10.1097/00005344-199911000-00013",
language = "English",
volume = "34",
pages = "711--717",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The protective effect of EGb 761 in isolated ischemic/reperfused rat hearts

T2 - A link between cardiac function and nitric oxide production

AU - Varga, E.

AU - Bodi, Annamaria

AU - Ferdinándy, P.

AU - Droy-Lefaix, Marie Therese

AU - Blasig, Ingolf E.

AU - Tósaki, A.

PY - 1999/11

Y1 - 1999/11

N2 - This study was conducted to evaluate the effect of Ginkgo biloba extract (EGb 761) on the nitric oxide (NO) production in relation to the recovery of postischemic cardiac function in isolated working rat hearts. Rats were orally treated with various doses (25, 50, 75, and 100 mg/kg/day) of EGb 761 for 10 days. Hearts were isolated in 'working mode' and subjected to 30-min ischemia followed by 120 rain of reperfusion. EGb 761 inhibited NO production measured by electron spin-resonance spectroscopy (ESR), and improved the recovery of postischemic cardiac function (coronary flow, aortic flow, left ventricular developed pressure and its first derivative) in the ischemic/reperfused myocardium. Thus in rats treated with 25, 50, 75, and 100 mg/kg/day of EGb 761 and in hearts subjected to 30-min ischemia followed by 120 min of reperfusion, aortic flow was increased from its postischemic drag- free control value of 8.0 ± 0.4 to 8.6 ± 0.4 ml/min (NS), 17.3 ± 0.9 ml/min (p <0.05), 21.5 ± 1.1 ml/min (p <0.05), and 23.6 ± 1.2 ml/min, respectively. The same recovery in postischemic coronary flow, left ventricular developed pressure, and its first derivative also was observed. In the initial phase of reperfusion, NO production measured by ESR was reduced by 85% in the 75 mg/kg/day of EGb 761-treated group in comparison with the drug-free ischemic/reperfused hearts. Inducible NO synthase (iNOS) messenger RNA (mRNA) measured by reverse transcription-polymerase chain reaction (RT-PCR) also was reduced by 41 and 58% in the groups treated with 75 and 100 mg/kg/day of EGb 761, respectively. Our findings show that EGb 761 directly acts as an NO scavenger and concomitantly inhibits the expression of iNOS mRNA. Thus, EGb 761 may act as a potent inhibitor of NO production under the condition of ischemia/reperfusion, improving the recovery of postischemic cardiac function.

AB - This study was conducted to evaluate the effect of Ginkgo biloba extract (EGb 761) on the nitric oxide (NO) production in relation to the recovery of postischemic cardiac function in isolated working rat hearts. Rats were orally treated with various doses (25, 50, 75, and 100 mg/kg/day) of EGb 761 for 10 days. Hearts were isolated in 'working mode' and subjected to 30-min ischemia followed by 120 rain of reperfusion. EGb 761 inhibited NO production measured by electron spin-resonance spectroscopy (ESR), and improved the recovery of postischemic cardiac function (coronary flow, aortic flow, left ventricular developed pressure and its first derivative) in the ischemic/reperfused myocardium. Thus in rats treated with 25, 50, 75, and 100 mg/kg/day of EGb 761 and in hearts subjected to 30-min ischemia followed by 120 min of reperfusion, aortic flow was increased from its postischemic drag- free control value of 8.0 ± 0.4 to 8.6 ± 0.4 ml/min (NS), 17.3 ± 0.9 ml/min (p <0.05), 21.5 ± 1.1 ml/min (p <0.05), and 23.6 ± 1.2 ml/min, respectively. The same recovery in postischemic coronary flow, left ventricular developed pressure, and its first derivative also was observed. In the initial phase of reperfusion, NO production measured by ESR was reduced by 85% in the 75 mg/kg/day of EGb 761-treated group in comparison with the drug-free ischemic/reperfused hearts. Inducible NO synthase (iNOS) messenger RNA (mRNA) measured by reverse transcription-polymerase chain reaction (RT-PCR) also was reduced by 41 and 58% in the groups treated with 75 and 100 mg/kg/day of EGb 761, respectively. Our findings show that EGb 761 directly acts as an NO scavenger and concomitantly inhibits the expression of iNOS mRNA. Thus, EGb 761 may act as a potent inhibitor of NO production under the condition of ischemia/reperfusion, improving the recovery of postischemic cardiac function.

KW - Cardiac function

KW - iNOS mRNA

KW - Ischemia

KW - Nitric oxide

KW - Rat heart

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=0032744519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032744519&partnerID=8YFLogxK

U2 - 10.1097/00005344-199911000-00013

DO - 10.1097/00005344-199911000-00013

M3 - Article

C2 - 10547088

AN - SCOPUS:0032744519

VL - 34

SP - 711

EP - 717

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 5

ER -